secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2022-09-21T23:59:59+00:00
Accession:  0001140361-22-034294
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.02, 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant terminates $250M Cantor purchase agreement, appoints new director
-------------------------------------------------------------------------

- Terminated $250M Common Shares Purchase Agreement with Cantor effective by Oct 5, 2022; entered new Sales Agreement with Cowen on Sept 19, 2022.
- Director Masayo Tada resigned effective Sept 16, 2022; no dispute with company or board.
- Board appointed Hiroshi Nomura (President/CEO of Sumitomo Pharma) as Class III director effective Sept 16, 2022; waived compensation.
- At Sept 15 AGM, shareholders elected Class I directors Gline, Manchester, Epperly and ratified Ernst & Young as auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/ny20005291x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-034294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer